论文部分内容阅读
中成药是否应该降价常引起争议。通过分析1995—2011年统计数据,结果发现:看病贵的主要责任并不在药品价格增长;对中药而言其价格指数上涨明显慢于药材价格上涨,1995年至今我国中成药生产的利润率受原料价格影响处于下降状态,如果再下调中成药价格对行业无疑是雪上加霜;中成药的成本有高有低,优劣原料价格平均相差1倍,如果再进行降价将把中成药逼向假劣药横行的状况。
Whether Chinese medicine should cut prices often cause controversy. By analyzing the statistical data from 1995 to 2011, it was found that the primary responsibility for seeing a doctor is not the increase in the price of medicines. For Chinese medicine, the price index rose significantly slower than that of medicinal herbs. Since 1995, the profit margin of Chinese patent medicine has been affected by raw materials If the price of Chinese medicine is further reduced, the industry is undoubtedly even worse. The cost of proprietary Chinese medicines will be on a high or low basis. The average price of good and bad raw materials will be double that of the average price. The situation.